Is nintedanib a targeted therapy?

Nintedanib (Nintedanib) is a targeted therapy drug classified as a tyrosine kinase inhibitor (TKI) and is mainly used for the treatment of idiopathic pulmonary fibrosis (IPF). Its mechanism of action is by targeting multiple receptor tyrosine kinases, such as vascular endothelial growth factor (VEGF) receptors, fibroblast growth factor (FGF) receptors, and platelet-derived growth factor (PDGF) receptors, thereby effectively inhibiting signaling pathways related to fibrosis and slowing down the progression of the disease.

Clinical studies have shown that nintedanib can significantly delay the decline of lung function in patients with idiopathic pulmonary fibrosis, especially the improvement in forced vital capacity (FVC). This property makes nintedanib an important option in the treatment of idiopathic pulmonary fibrosis. According to relevant studies, the recommended dosage regimen is 150 mg twice daily, which achieves a good balance between efficacy and tolerability.

In addition to the application of idiopathic pulmonary fibrosis, research on nintedanib in other fibrotic diseases is also ongoing. For example, in animal models of systemic sclerosis (SSc), nintedanib demonstrated anti-fibrotic, anti-inflammatory, and improved vascular remodeling effects, suggesting its potential in the treatment of a wider range of fibrotic diseases. As its mechanism of action is further studied, more indications may be discovered in the future.

However, certain side effects may occur with the use of nintedanib, including diarrhea, nausea, vomiting, and abnormal liver function. Therefore, during the medication process, doctors usually pay close attention to the patient's response and make adjustments according to the specific situation. In addition, patients should be followed up regularly during treatment to ensure efficacy and safety, and to deal with possible side effects in a timely manner.

Reference materials:https://www.sciencedirect.com/topics/medicine-and-dentistry/nintedanib